View Post

Alpha-TEA helps with breast cancer

In Clinical Trials by Barbara Jacoby

By: Christina Burkhart From: abc12.com One in eight women will be diagnosed with breast cancer at some point in her lifetime. One in four of those breast cancer diagnosis will be HER-2-positive. It’s an aggressive form of breast cancer and is more likely to recur than HER2-negative breast cancer. Now a new trial is underway to stop this cancer in …

View Post

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

In Clinical Trials by Barbara Jacoby

Source: Molecular Templates, Inc. From: globenewswire.com Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types  HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is Reached Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage …

View Post

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788

In Clinical Trials by Barbara Jacoby

Source: Ambrx Inc. From: prnewswire.com – 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU – Multiple Global Phase 2/3 Trials to Begin Early 2021 Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, provided a clinical …

View Post

Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program

In Clinical Trials by Barbara Jacoby

Source: Shasqi From: PR Newswire First Patients Dosed in Phase 1 Clinical Study of SQ3370 for Advanced Solid Tumor Malignancies Shasqi is First Y-Combinator Biotech Company to Reach First-in-Human Clinical Studies Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform, announced today the first-ever application of click chemistry in …

View Post

Phase 1 human trials suggest UIC-developed breast cancer drug is safe, effective

In Clinical Trials by Barbara Jacoby

By: University of Illinois at Chicago From: newswise.com A new type of breast cancer drug developed by researchers at the University of Illinois Chicago can help halt progression of disease and is not toxic, according to phase 1 clinical trials. The drug is specifically designed for women whose cancer has stopped responding to hormone therapy. The results are published in the journal Breast …

View Post

Phase 1 Trials: What to Expect

In In The News by Barbara Jacoby

By: Andrea S. Blevins Primeau, PhD, MBA From: cancertherapyadvisor.com A phase 1 clinical trial is typically a first-in-human study of an experimental therapy, and its historical purpose was to evaluate the safety and identify potential side effects of that investigational treatment, as well as determine an appropriate dosage for use.1 The American Society of Clinical Oncology (ASCO) states that phase 1 …

View Post

A new cancer drug might stop tumors in their tracks

In Clinical Trials by Barbara Jacoby

By: Chris Smith From: bgr.com A new type of cancer drug has shown promising results in Phase 1 trials after preventing tumor growth in more than half of patients who did not have access to any other treatment. Called berzosertib, the drug is part of “precision medicine” therapies that target specific genes or genetic changes. Berzosertib works best when combined …

View Post

Alpha-TEA and Concurrent Trastuzumab Under Exploration in Refractory HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Brittany Cote From: onclive.com William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research. Concurrent treatment with α-tocopheryloxyacetic acid (TEA) and trastuzumab (Herceptin) could possess the potential to induce clinical activity and augment type 1 (Th1) antitumor immunity in patients with HER2-positive metastatic breast cancer who have …

View Post

Alteogen confirms safety, efficacy of HER2 breast cancer therapy

In Clinical Trials by Barbara Jacoby

By: Shim Hyun-tai From: koreabiomed.com The American Society of Clinical Oncology (ASCO) is one of the most noteworthy events in the global biotech industry as it provides an opportunity to gauge the clinical success of pipelines for pharmaceuticals on the global stage. This is the sixth in a series of articles Korea Biomedical Review publishes to present the key clinical …

View Post

A Novel Mechanism of Action for FS118 and the Potential to Overcome PD-(L)1 Resistance Published in Clinical Cancer Research

In Clinical Trials by Barbara Jacoby

From: businesswire.com F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific antibodies (mAb2™), today announces the publication in Clinical Cancer Research of preclinical data highlighting the potential novel mechanism of action of its wholly-owned lead clinical asset FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody. FS118 is currently …